MedWatch

Investors: Novo Nordisk's obesity efforts will lead to growth

Obesity will continue to be a huge health problem, which means a lot of growth potential for the company, one analyst says.

Photo: Novo Nordisk / PR

Danish firm Novo Nordisk's share price has experienced a boost on the stock exchange over the past few months, and the party is far from over.

Investors and analysts believe that the company's venture into the obesity market will be rewarded with large growth, Danish business daily Børsen reports.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs